Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial

The Lancet HIV

Volumn 3, Issue 9, 2016, Pages e421-e430

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; C REACTIVE PROTEIN; D DIMER; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; SERUM AMYLOID A; THROMBOMODULIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAINTNESS; FEMALE; GYNECOMASTIA; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SPONTANEOUS ABORTION; SUICIDAL IDEATION; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS LOAD; YOUNG ADULT; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FRANCE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; VIROLOGY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; YOUNG ADULT;

EID: 84991373001     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(16)30054-6     Document Type: Article

References (30)

1. 1 INSIGHT START Study Group, Lundgren, JD, Babiker, AG, Gordin, F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373 (2015), 795–807.
2. 2 WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd edn., 2016, World Health Organisation, Geneva http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf (accessed June 10, 2016).
3. 3 British HIV Association. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. http://www.bhiva.org/documents/Guidelines/Treatment/2015/2015-treatment-guidelines.pdf, 2015 (accessed Jan 13, 2016).
4. 4 Lowenthal, ED, Bakeera-Kitaka, S, Marukutira, T, Chapman, J, Goldrath, K, Ferrand, RA, Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. Lancet Infect Dis 14 (2014), 627–639.
5. 5 Kim, SH, McDonald, S, Kim, S, Foster, C, Fidler, S, Importance of self-motivation and social support in medication adherence in HIV-infected adolescents in the United Kingdom and Ireland: a multicentre HYPNet study. AIDS Patient Care STDS 29 (2015), 354–364.
6. 6 Foster, C, McDonald, S, Frize, G, Ayers, S, Fidler, S, “Payment by Results”—financial incentives and motivational interviewing, adherence interventions in young adults with perinatally acquired HIV-1 infection: a pilot program. AIDS Patient Care STDS 28 (2014), 28–32.
7. 7 Dybul, M, Nies-Kraske, E, Dewar, R, et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis 189 (2004), 1974–1982.
8. 8 Dybul, M National Institute of Allergy and Infectious Disease US National Institutes of Health, USA. Approaches to interrupting HAART for the treatment of HIV infection. IAPAC sessions 2001, July 18–19, 2001—Chicago. IAPAC Mon 7 (2001), 232–234.
9. 9 Casseb, J, Da Silva Duarte, AJ, Structured intermittent therapy with seven-day cycles of HAART for chronic HIV infection: a pilot study in Sao Paulo, Brazil. AIDS Patient Care STDS 19 (2005), 425–428.
10. 10 Reynolds, SJ, Kityo, C, Hallahan, CW, et al. A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One, 5, 2010, e10307.
11. 11 Ananworanich, J, Nuesch, R, Le Braz, M, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 17 (2003), F33–F37.
12. 12 Rudy, BJ, Sleasman, J, Kapogiannis, B, et al. Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. AIDS Res Hum Retroviruses 25 (2009), 555–561.
13. 13 Leibowitch, J, Mathez, D, de Truchis, P, et al. Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: the ICCARRE project. FASEB J 29 (2015), 2223–2234.
14. 14 Cohen, C, Colson, A, Pierone, G, et al. The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapy. J Int AIDS Soc, 11, 2008, O19.
15. 15 Cohen CJ, Colson A, Pierone G, Dejesus E, et al. FOTO study: the 48 week extension to assess durability of the strategy of taking efavirenz, tenofovir and emtricitabine five days on, two days off (FOTO) each week in virologically suppressed patients. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; Cape Town, South Africa; July 19–22, 2009. Abstr MOPE B063.
16. 16 Lamorde, M, Schapiro, JM, Burger, D, Back, DJ, Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach. AIDS 28 (2014), 2551–2563.
17. 17 Bernays S, Seeley J, Paparini S, Rhodes T. ‘I am scared of getting caught up in my lie’: challenges to self-reported adherence for young people living with HIV. AIDS Impact; Amsterdam, the Netherlands; July 28–31, 2015. Abstr 3435.
18. 18 US Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1.0, December, 2004; clarification August. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf, 2009 (accessed Jan 4, 2016).
19. 19 Carpenter, JB, Bithell, J, Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 19 (2009), 1141–1164.
20. 20 PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker, A, Castro nee Green, H, Compagnucci, A, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 11 (2011), 273–283.
21. 21 Eriksson, S, Graf, EH, Dahl, V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog, 9, 2013, e1003174.
22. 22 Williams, JP, Hurst, J, Stohr, W, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife, 3, 2014, e03821.
23. 23 Saez-Cirion, A, Bacchus, C, Hocqueloux, L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog, 9, 2013, e1003211.
24. 24 Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr, WM, Lundgren, J, Neaton, JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006), 2283–2296.
25. 25 Tenorio, AR, Zheng, Y, Bosch, RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 210 (2014), 1248–1259.
26. 26 Krishnan, S, Wilson, EM, Sheikh, V, et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis 209 (2014), 931–939.
27. 27 Klein, N, Sefe, D, Mosconi, I, et al. The immunological and virological consequences of planned treatment interruptions in children with HIV infection. PLoS One, 8, 2013, e76582.
28. 28 ENCORE1 Study Group, Puls, R, Amin, J, Losso, M, et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 383 (2014), 1474–1482.
29. 29 WHO. What's new in HIV treatment. Fact Sheet. November 2015, 2015, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/204347/1/WHO_HIV_2015.44_eng.pdf (accessed Jan 13, 2016).
30. 30 Elliot, E, Amara, A, Jackson, A, et al. Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. J Antimicrob Chemother 71 (2016), 1031–1036.